|Slideshows|July 5, 2018

The Brave New World of Inflammation

The immune-brain loop: a world where more and more clinicians boldly go-and thrive-among new discoveries.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

ByLeah Kuntz

June 22nd 2026

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

ByAntonio Vita, MD, PhD,Gabriele Nibbio, MD, PhD,Stefano Barlati, MD

June 19th 2026

Treating Patients With First-Episode Psychosis: Lessons From McLean OnTrack

ByMichael Murphy, MD, PhD,Allison Nelson-Eliot, LICSW

June 18th 2026

Assessment of Suicide Risk in Individuals With Schizophrenia

ByCarla Kotzé, PhD, MMed, MPhil, FCPsych,Johannes Lodewikus Roos, MD, DSc, MMed, FCPsych

June 17th 2026

Safety and Efficacy of Intranasal Esketamine for Major Depressive Disorder and Treatment-Resistant Depression

ByNick Ratzloff, DO,Ayse K. Coskun, MD,Kari Wolatz, MD,Albert Dickan, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

June 15th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

The Brave New World of Inflammation

Related Content

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

Treating Patients With First-Episode Psychosis: Lessons From McLean OnTrack

Assessment of Suicide Risk in Individuals With Schizophrenia

Safety and Efficacy of Intranasal Esketamine for Major Depressive Disorder and Treatment-Resistant Depression

Latest CME

Southern California Psychiatry Conference

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Trending on Psychiatric Times

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults

Evaluating Transdermal Asenapine in Schizophrenia

Empowering Patients and Expanding Formulation Options in Schizophrenia Care